What happened to the CSL (ASX:CSL) share price in 2020?

It has been a volatile year for the CSL Limited (ASX:CSL) share price in 2020. Here's what you need to know about the last 12 months…

| More on:
ResMed share price healthcare asx share price flat represented by doctor shrugging

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

It has been a bit of a mixed year for the CSL Limited (ASX: CSL) share price in 2020.

Although the biotherapeutics giant's shares are on the cusp of recording a gain of almost 5% for the year, it could have been so much more.

Prior to the pandemic, the CSL share price was up almost 25% year to date. But since then, the company's shares have gradually given back the majority of these gains.

What happened in 2020?

CSL has actually had a very positive year all things considered.

In FY 2020, the company delivered a strong result and looks set to build on this in the current financial year.

For example, for the 12 months ended 30 June 2020, CSL delivered a 7.2% increase in reported sales revenue to US$8,797 million. This was driven by solid growth from both its CSL Behring and Seqirus vaccines businesses during the year.

CSL Behring delivered an 8% increase in constant current sales to US$7,661 million. The key driver of this was demand for its immunoglobulins, which recorded a 22% lift in sales to US$4,014 million.

Whereas Seqirus sales increased 11% in constant currency terms to US$1,297 million. This was driven by a 21% lift in seasonal influenza vaccine sales during the 12 months.

And thanks to margin improvements, CSL's earnings grew at an even quicker rate. The company's net profit after tax came in at US$2,103 million. This was up 17% in constant currency terms and 9.6% on a reported basis.

What about FY 2021?

Despite facing headwinds from the COVID-19 pandemic, CSL is forecasting further growth in FY 2021.

It is guiding to a net profit after tax of approximately US$2.170 billion to US$2.265 billion in constant currency. This implies year on year growth of 3% to 8%.

Why is the CSL share price underperforming?

There have been a couple of things weighing on the company's shares this year.

The first is the COVID-19 pandemic and its impact on plasma collections. Plasma is a key ingredient in its immunoglobulins products, which, as you can see above, contribute just under half of the company's overall sales.

Collections have been challenging because of lockdowns and social distancing initiatives, which has led to higher prices being paid for donations. This will have an impact on the margins of these products in the future.

Also weighing on its shares was recent news that it has pulled the plug on a potential COVID-19 vaccine that was undertaking clinical trials.

While the vaccine is believed to have been highly successful at fighting COVID-19, the molecular clamp component of the vaccine was triggering false positives for HIV.  

Following advice from experts, CSL worked through the implications that this issue presents to rolling out the vaccine into broad populations. It generally agreed that significant changes would need to be made to well-established HIV testing procedures.

These changes were ultimately deemed too great, leading to CSL and the Australian Government agreeing the vaccine development will not proceed to Phase 2/3 trials.

Can the CSL share price go higher in 2021?

If analysts at UBS are to be believed, there could be strong gains ahead for the CSL share price in 2021.

The broker is positive on the company and has a buy rating and $346.00 price target on its shares. This price target implies potential upside of ~20% over the next 12 months.

James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. owns shares of CSL Ltd. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Share Market News

A young smiling couple out hiking enjoy a view from the top of the mountains.
Share Gainers

Here are the top 10 ASX 200 shares today

Investors enjoyed a rosy end to the trading week this Friday.

Read more »

A fun depiction of summer Santa Claus -- wearing red swimming trunks and Hawaiian shirt -- sitting in a deck chair on his laptop at the beach.
Opinions

2 ASX stocks on my naughty list this Christmas

Nothing but coal in the stockings of these disappointing companies.

Read more »

Man raising both his arms in the air with a piggy bank on his lap, symbolising a record high.
Record Highs

The multi-billion-dollar ASX tech share hitting new highs on broker bullishness

This ASX tech share darling is up 216% in the year to date and just reset its record price.

Read more »

Cheerful businessman with a mining hat on the table sitting back with his arms behind his head while looking at his laptop's screen.
Resources Shares

Fortescue shares are galloping again as Twiggy stays confident in China's horsepower

It's business as usual for the miner despite Trump's promised 60% tariffs on Chinese imports.

Read more »

A graphic showing a businessman running up a white upwards rising arrow symbolising the soaring Magellan share price today
Share Gainers

How these 3 ASX 200 stocks led the charge higher this week

The three top ASX 200 stocks are up 14% to 34% this week.

Read more »

Businessman working and using Digital Tablet new business project finance investment at coffee cafe.
Broker Notes

Brokers name 3 ASX shares to buy today

Here's why brokers are feeling bullish about these three shares this week.

Read more »

A man clenches his fists in excitement as gold coins fall from the sky.
Share Gainers

Why Imugene, Neuren, Sigma, and Smartgroup shares are charging higher

These shares are ending the week on a high. But why? Let's find out.

Read more »

A man sits in despair at his computer with his hands either side of his head, staring into the screen with a pained and anguished look on his face, in a home office setting.
Share Fallers

Why Arcadium Lithium, Block, Jumbo, and Mineral Resources shares

These shares are ending the week in the red. Why are investors selling them?

Read more »